ImmunoGen Investor Relations Material
Latest events
Q3 2023
ImmunoGen
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ImmunoGen Inc
Access all reports
ImmunoGen, Inc., is a clinical-stage biotechnology company. The company develops antibody-drug conjugate therapies to treat cancer. Its ADC product candidates include Binimetinib, an ADC designed to treat non-small cell lung cancer, colorectal cancer, and pancreatic cancer; Daratumumab, an ADC designed to treat multiple myeloma; and SAR302503, an ADC that combines trastuzumab with an anthracycline. The company's ADC product candidates are currently in various stages of clinical development. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
IMGN
Country
🇺🇸 United States